Literature DB >> 28340645

Transgender hormone therapy: understanding international variation in practice.

Yaasir Mamoojee1, Leighton J Seal2, Richard Quinton3.   

Abstract

Mesh:

Year:  2017        PMID: 28340645     DOI: 10.1016/S2213-8587(17)30068-2

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  6 in total

Review 1.  Contraception across transgender.

Authors:  Ilaria Mancini; Stefania Alvisi; Giulia Gava; Renato Seracchioli; Maria Cristina Meriggiola
Journal:  Int J Impot Res       Date:  2021-02-08       Impact factor: 2.896

2.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.

Authors:  E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus
Journal:  Int J Transgend Health       Date:  2022-09-06

Review 3.  Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population.

Authors:  Gloria Aranda; Irene Halperin; Esther Gomez-Gil; Felicia A Hanzu; Núria Seguí; Antonio Guillamon; Mireia Mora
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-30       Impact factor: 5.555

4.  Use of Hormones Among Trans Women in the West Coast of Peninsular Malaysia: A Mixed Methods Study.

Authors:  Abdul Rashid; Siti Nur Afiqah; Yufu Iguchi
Journal:  Transgend Health       Date:  2022-06-13

5.  An Approach to Nonsuppressed Testosterone in Transgender Women Receiving Gender-Affirming Feminizing Hormonal Therapy.

Authors:  Arvind Maheshwari; Todd Nippoldt; Caroline Davidge-Pitts
Journal:  J Endocr Soc       Date:  2021-04-16

6.  Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.

Authors:  Suzanne M E Kuijpers; Chantal M Wiepjes; Elfi B Conemans; Alessandra D Fisher; Guy T'Sjoen; Martin den Heijer
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.